Searchable abstracts of presentations at key conferences in endocrinology

ea0086p278 | Reproductive Endocrinology | SFEBES2022

Severe Virilization due to ovarian hyperthecosis

Wellala Vindya , Bulugahapitiya Uditha

Approximately 10% of the female present with features of hyperandrogenism in their life. It is common in adolescent and childbearing age and less common in menopausal age. A 56-year-old female with a history of type 2 diabetes mellitus, hypertension presented with progressively worsening features of virilization for 1 year. Patient had severe hirsutism, androgenic alopecia and clitoromegaly. She had no loss of weight, loss of appetite suggestive of underlying malignancy. Howev...

ea0086p180 | Bone and Calcium | SFEBES2022

Parathyromatosis

Wellala Vindya , Wijethunga Udai , Bulugahapitiya Uditha

Parathyromatosis is a persistent or recurrent hyperparathyroidism following parathyroidectomy. It usually presents as multiple nodules in the neck. Infrequently may present as a single palpable neck mass. It could be due to low grade malignancy, seeding of parathyroid tissue during parathyroidectomy and growth of persistent embryonic foci of parathyroid tissue. A 24-year-old patient presented with features of hypercalcaemia. She has undergone left inferior parathyroidectomy 1 ...

ea0086p108 | Neuroendocrinology and Pituitary | SFEBES2022

Dopamine agonist intolerance in prolactinoma- A management challenge to endocrinologist

Wellala Vindya , Machenahalli Pratibha , Kumarathunga Dineesha , Georgios Giovos , Puja Thadani

Introduction: Typically, patients with a microprolactinoma will have serum prolactin level between 2,000-4,000mIU/l. The primary goal of treatment is to normalise prolactin level and thereby improve symptoms associated with a raised prolactin. Dopamine (D2) agonists are the main stay of treatment with some patients unable to tolerate dopamine agonists rather than being resistant to the medication.Case report: A 26-year-old lady with a history of anxiety ...

ea0091cb54 | Additional Cases | SFEEU2023

Complexities in the diagnosing of Cushing’s syndrome

Wellala Vindya , Ranganatha Rao , Kumarathunga Dineesha , Thadani Puja , Georgios Giovos

Diagnosis of Cushing’s syndrome is challenging in the absence of cardinal features. But still, they have the same metabolic risk due to the presence of biochemical hypercortisolism. A 35-year lady was referred to the tertiary care endocrine unit following an incidental finding of high cortisol levels while on treatment for covid in 2021. She also had some weight gain, slow healing of wounds, and easy bruising. She did not have any features of hyperandrogenism and hyperten...

ea0091we8 | Workshop E: Disorders of the gonads | SFEEU2023

A case of non obstructive azoospermia

A D M Kumarathunga P , Wellala Vindya , Yovos George , Thadani Puja , Randeva Harpal

Introduction: Infertility is a common medical condition affecting 50 million couples worldwide and azoospermia account for around 10 % of cases of male infertility. Non-obstructive azoospermia is one of the most severe forms of male infertility and aetiology could be due to primary testicular failure, secondary testicular failure and those with incomplete or ambiguous picture of testicular failure.Case report: A 34-year-old patient referred to endocrine ...

ea0099ep947 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Changes in sex hormone levels after bariatric surgery and its association with weight loss in morbidly obese patients

Wellala Vindya , Wijethunga Udai , Udith Bulugahapitiya Dr. , Jayasuriya Anuradha , Karunarathna Hasani

Introduction: Bariatric surgery has become an essential option for long-term weight loss in morbidly obese population.Objective: This study was aimed at investigating the effects of bariatric surgery on sex hormone levels and potential hormonal changes associated with significant weight loss in a cohort of 49 patients with obesity.Methodology: Forty-nine patients with obesity, scheduled for bariatric surgery in Colombo South Teachi...

ea0099ep734 | Adrenal and Cardiovascular Endocrinology | ECE2024

Hydrocortisone vs prednisolone for treatment of adrenal insufficiency disease (HYPER-AID Study) – interim results from a single, tertiary care centre

Maria Leca Bianca , Thadani Puja , Dineesha Kumarathunga Dineesha , Wellala Vindya , Davasgaium Allan , George Rojet , Seehra Parminder , Mattu Rajan , Randeva Harpal S.

Introduction: Adrenal insufficiency (AI) requires lifelong steroid replacement therapy, traditionally with hydrocortisone (HC), which, taken in divided doses, mimics the normal daytime cortisol profile. Prednisolone, with its longer duration of action, presents a cost-effective, once-daily alternative, yet its comparative efficacy and safety profile in AI management still need to be explored. Therefore, the current study aims to assess the metabolic and cardiovascular outcomes...